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Colorectal cancer (CRC) is the second leading cause
of cancer-related mortality in Europe and USA, and
approximately 300,000 new cases and 200,000 deaths
due to CRC are reported in these areas annually 
[1]. CRC is also the third major cause of cancer-related
death in Taiwan, with over 7,000 new cases and 
3,000 deaths/year [2]. With the recent advent of
improvements in prognosis, many CRC patients may
survive for longer after treatment. However, these
patients are expected to be at increased risk of 
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Most cancer patients often neglect the possibility of secondary cancer. Colorectal cancer (CRC) is
the third leading cause of cancer death in Taiwan. It is important to be aware of the clinical char-
acteristics of double cancer in CRC patients for early diagnosis and treatment. We retrospectively
analyzed 1,031 CRC patients who underwent surgical treatment at the Department of Surgery of
Kaohsiung Medical University Hospital between January 1998 and December 2004. Among these
patients, CRC was accompanied by cancer of other organs in 17 patients (1.65%), either synchro-
nously or metachronously. Therefore, we describe our experience regarding the location of CRC,
the clinical symptoms and signs of these patients, the TNM stage, histology, phase, association
with other malignancies, interval between cancers and clinical outcomes. Of the 17 patients in
whom CRC was accompanied by primary cancer of other organs, there were four synchronous
and 13 metachronous multiple cancer patients. Our patient group comprised six men and 11
women with ages ranging from 47 to 88 years (median age, 66 years). The most common location
of CRC was the sigmoid colon. Six gastric cancers (35.2%) and six breast cancers (35.2%) were
associated with primary CRC. The remaining six second primary cancers were one lung cancer,
one thyroid cancer, one cervical cancer, one ovarian cancer, one skin cancer, and one urinary
bladder cancer. Of the 13 metachronous multiple cancer patients, eight patients developed subse-
quent CRC after primary cancers of other organs, whereas two patients developed a subsequent
second primary cancer after CRC. The intervals between the development of metachronous mul-
tiple cancers ranged from 2 to 19 years. In this retrospective analysis, breast and gastric cancer
patients were at increased risk of developing subsequent secondary CRC. Careful attention
should always be paid to the possibility of secondary CRC in treating these cancer patients.
Cancer patients with hematochezia or gastrointestinal symptoms/signs should be evaluated for
the possibility of second primary CRC during their regular follow-up.
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developing second other-site primary cancers, or they
may redevelop CRC after primary cancer of other
organs. Although synchronous and metachronous
CRC are now well known to all colorectal surgeons,
second other-site primary cancers accompanying CRC
are unfamiliar to most colorectal physicians. Knowl-
edge of the clinical characteristics of these second pri-
mary cancers becomes important especially during
postoperative surveillance of these patients. In this
article, we describe our clinical experience of CRC
patients with other associated primary cancers, and
review the literature.
MATERIALS AND METHODS
Between January 1998 and December 2004, 1,031 spo-
radic CRC patients underwent surgical treatment at
the Department of Surgery of Kaohsiung Medical
University Hospital. Among these patients, CRC was
accompanied by cancer of other organs in 17 (1.65%),
either synchronously or metachronously. The inclu-
sion criteria were that each tumor had to have a defi-
nite histologic picture of malignancy, and clearly no
origin of metastasis from another tumor. Second can-
cers detected within 1 year after the detection of the
initial cancers were regarded as synchronous cancers.
The medical records including patients’ demograph-
ics, clinical and pathologic features, operative details,
and outcomes were retrospectively reviewed. Clinical
stage and pathologic features of primary CRC were
defined according to the criteria of the American Joint
Commission on Cancer [3].
RESULTS
Table 1 lists the demographics and clinical features of
CRC patients with other primary cancers. There were
four synchronous and 13 metachronous multiple can-
cer patients. The group comprised six men and 11
women with ages ranging from 47 to 88 years (median
age, 66 years). The most common site of CRC was the
sigmoid colon. Primary cancers of other organs were six
breast cancers (35.2%) and six gastric cancers (35.2%).
The remaining six cancers included one lung cancer,
one thyroid cancer, one cervical cancer, one ovarian
cancer, one skin cancer, and one urinary bladder cancer.
One patient had triple primary cancers involving the
stomach, breast, and colon.
The intervals between the development of multiple
primary cancers ranged from 2 to 19 years. The TNM
stages of the CRC patients were as follows: five
patients were stage I (29.4%), three patients were
stage II (17.6%), seven patients were stage III (41.2%),
and two patients were stage IV (11.8%). With regard
to the histologic types of these tumors, six (35.3%)
were well-differentiated carcinoma, eight (47.1 %) were
moderately differentiated carcinoma, and three (17.6%)
were poorly differentiated carcinoma. Of the 13 meta-
chronous multiple cancer patients, 11 developed sub-
sequent CRC after cancers of other organs, whereas
two patients developed subsequent primary cancer
after CRC. Most of the synchronous double cancer
patients (3/4, 75%) were gastric cancer combined with
CRC. Most of the CRC patients (15/17) were diag-
nosed by colonoscopy due to the presence of hema-
tochezia or gastrointestinal symptoms/signs, while
two CRC patients with severe bowel obstruction
were diagnosed by abdominal computed tomogra-
phy (Table 2). The most common clinical symptoms
and signs included hematochezia, followed by abdom-
inal pain, constipation, anemia, and ileus. To date,
most patients have survived, but two stage IV
patients died of CRC due to delayed diagnosis of the
disease.
DISCUSSION
CRC is a leading cause of death in the Western world,
and it has also become the third leading cause of death
from cancer in Taiwan. Survival can be improved if
the disease is detected earlier. Cancer-bearing patients
are assumed to be at increased risk of developing
cancers of other organs [4]. The rapidly increas-
ing rate of CRC in recent years has drawn special
attention to this site in terms of synchronous and
metachronous malignancies of other organs. In this
current investigation, the incidence of a second other-
site primary cancer is 1.65%, which is within the
range of 1.26–3.3% from previous reports [5–7].
Of these 17 cases, breast and gastric cancer
patients had the highest risk of second cancer for
CRC. Our results are consistent with those of a
Japanese research group [5,8], where gastric cancer
Colorectal cancer patients with primary cancer of other organs
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predominates among CRC patients with primary
cancer of other organs. Ueno et al indicated that
when colon cancer was combined with other cancers,
stomach cancer (1.4%) was the most frequently encoun-
tered neoplasm, followed by breast cancer (0.4%);
and when rectal cancer was combined with other
cancers, stomach cancer (0.6%) was also the most fre-
quently encountered neoplasm, but this was followed
by lung cancer (0.5%) [5]. Consequently, we should
closely follow up and ascertain the possibility of
developing secondary CRC among gastric and breast
cancer patients postoperatively. Conversely, our inci-
dence of lung cancer together with CRC is only 0.1%,
which is far less than the Japanese study. Another
research group from Taiwan [7] observed that the
most common second other-site primary cancer in
CRC patients was the liver, and this was followed by
the stomach. Recently, the decreasing incidence of
hepatoma in Taiwan may possibly explain this phe-
nomenon. Furthermore, there is an increased risk of
developing breast or reproductive organ cancer in
women who survive CRC [9–12]. Screening for col-
orectal tumors in women with a past history of breast,
uterine, or ovarian malignancies is suggested [12]. It
was reported that cervical cancer was the most pre-
dominant malignancy associated with CRC, followed
by gastric cancer in the past [13]. However, with the
increasing incidence of breast cancer in developed
countries in recent years, breast cancer has become the
highest risk malignancy accompanying CRC.
Most patients have the symptoms and signs of
hematochezia or bowel habit change, and the disease
is usually diagnosed by colonoscopy. The essentials
of colonoscopy for patients with previous malig-
nancy must be kept in mind. A significantly higher
proportion of TNM stage I CRC (29.4%) would be
responsible for the favorable clinical outcomes of
these patients in our investigations. Early diagnosis
and surgical intervention should also be emphasized,
though two patients were diagnosed as late as stage
IV. We observed three gastric cancers of four synchro-
nous second other-site primary cancers among our
CRC patients, and these findings raised an issue of
performing upper gastrointestinal endoscopy before
management of CRC. Ueno et al suggested that all
CRC patients should undergo screening by upper
gastrointestinal endoscopy before operation [5]. In
addition, they recommend repeated upper gastroin-
testinal endoscopy at 2-year intervals during the first 5
years after operation. However, its cost-effectiveness
remains to be further evaluated. We suggest that CRC
patients with gastrointestinal symptoms or signs
should be carefully evaluated and checked up for the
necessity of upper gastrointestinal endoscopy in
advance. Precursor lesions (adenomatous polyps)
almost always precede the development of the neo-
plasm by several years. In our study, one gastric cancer
patient who had undergone transanal polypectomy 15
years previously and who was lost to follow-up unfor-
tunately developed unresectable rectal cancer later.
Systematic surveillance for second cancer is
essential after cancer surgery. A good surveillance
program should be cost-effective, and more detailed
analysis is mandatory for the high-risk sites of develop-
ing second cancers. Breast and gastric cancer patients
in particular have high risk for second cancers of
CRC. Patients presenting with hematochezia or other
gastrointestinal symptoms/signs should be carefully
evaluated.
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